Woman has burning sensation in legs after vacation — then doctors find brain parasites
When the woman first returned home to the coast of New England, she felt fatigued and attributed it to jet lag from weeks of traveling, according to a Feb. 13 case report published in the New England Journal of Medicine.
Her lack of energy was accompanied by a slight burning sensation in her feet, according to the case report, and she took some ibuprofen to help alleviate the pain.
The medications were unsuccessful, and over the next eight days, the burning sensation spread up her body into her legs, doctors said.
The pain got worse when her legs were touched, according to the report, and she went to the emergency room.
Burning spreads to the chest
The woman went through a series of tests — she had a normal temperature, heart rate, blood pressure and blood oxygen saturation — and she was sent home with instructions to follow up with her primary care physician, doctors said.
But over the next three days, the burning feeling spread up to her chest and arms and she developed a headache that wouldn't wane even with over-the-counter pain medication, according to the report.
The woman went back to the emergency room, but again showed normal tests, so she was given intravenous pain medications that helped her still-pounding headache and was sent home with the same instructions, doctors said.
'After the patient arrived home from the emergency department, she took zolpidem ((a drug for insomnia) which had been prescribed for a family member) to help with sleep. On the day of the current presentation, confusion developed,' doctors said. 'In the morning when she awoke, she thought she needed to pack for vacation and was not redirectable when her roommate attempted to help her lie back down in bed. When confusion did not resolve after several hours, the patient's partner brought her to this hospital for further evaluation.'
Sushi, street food-filled vacation
Then, doctors learned more about her trip.
In Bangkok, Thailand, she toured the city and stopped for street food along the way, but said she didn't eat anything raw, according to the report. Her next stop was Tokyo, Japan, where she said she mainly stayed in the hotel, but ate sushi throughout her stay. The majority of her trip was spent in Hawaii swimming in the ocean and eating salads and sushi.
Her newly developed confusion led doctors to try new tests, including a lumbar puncture, a procedure that taps into the spine to test the cerebrospinal fluid, according to the report.
The fluid underwent a diagnostic test, and finally the woman had an answer — she had parasites in her brain.
Doctors discovered Angiostrongylus cantonensis, a parasitic species of roundworm also called rat lungworm.
An A. cantonensis infection can lead to human eosinophilic meningitis, which the woman was experiencing.
'Human infection, which was initially described in Taiwan, is now distributed across many tropical and subtropical regions in southeast Asia and the Pacific Islands (including Hawaii), with expanding distribution that now includes locally acquired infections in Europe, Australia, the southern United States and the Caribbean,' doctors said. 'Only five cases of angiostrongyliasis were confirmed in Hawaii in 2024; however, given that 9 to 10 million tourists visit Hawaii each year, many people may have been exposed to infection but may not have symptoms until after they leave Hawaii.'
The infection can come from a few sources: raw or undercooked snails or slugs, vegetables or fruit that have been contaminated by snails, slugs or flatworms or their slime, or by eating infected hosts like land crabs, freshwater prawns or frogs, doctors said.
It can take as many as 14 days after the parasites are ingested for symptoms to begin, according to the report.
Symptoms usually begin as headache, nausea, vomiting and fever, but then can spread to neurological symptoms after the parasite leaves the bloodstream, enters muscle, migrates to peripheral nerves and into the spinal column and brain, doctors said.
The woman was treated with a directed therapy of medications — albendazole, prednisone, gabapentin and amitriptyline — and her headache and burning sensation went away, doctors said. She was able to return home after six days in the hospital to recover.
The medical team includes Joseph Zunt, Amy K. Barczak and Daniel Y. Chang.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
08-08-2025
- Yahoo
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic Islet Cells Without Immunosuppression and Overcome Both Allogeneic and Autoimmune Rejection Six-Month Patient Follow-up Results Presented at the 85th Annual American Diabetes Association (ADA) Scientific Sessions Further Demonstrate that Sana's HIP-Modified Pancreatic Islet Cells are Safe and Well-tolerated, Survive, Evade Detection by the Immune System, and Continue to Produce Insulin in the Patient Sana Is Incorporating its HIP Technology to Develop SC451, a HIP-Modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal Blood Glucose with No Insulin and No Immunosuppression Recent FDA INTERACT Meeting Increases Confidence in Moving Forward with GMP Master Cell Bank for SC451 and in Filing SC451 Investigational New Drug Application (IND) as Early as 2026 Sana Expects Study Data to Be Generalizable across Multiple Cell Types and Patient Populations SEATTLE, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the New England Journal of Medicine (NEJM) has published a journal article titled 'Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression' (DOI: 10.1056/NEJMoa2503822). The article discusses 12-week results from an investigator-sponsored trial, conducted at Uppsala University Hospital, evaluating the transplantation of UP421, a primary human pancreatic islet cell therapy engineered with Sana's hypoimmune (HIP) technology, without the use of immunosuppressive medications in a 42-year-old patient living with type 1 diabetes for over three decades. The intramuscular transplantation of HIP-modified pancreatic islet cells is safe and well-tolerated and demonstrates that these cells evade autoimmune and allogeneic immune recognition, persist, and secrete insulin in a glucose-dependent manner over the 12-week evaluation period reported in the article. 12-week PET-MRI scanning also confirmed islet cells at the transplant site. Six-month data, described below, were recently presented at the ADA meeting and presented today at the World Transplant Congress 2025 concurrently with the publication of the NEJM article. 'We are thrilled to have the results of this study, which we believe represent both a scientific and medical breakthrough, recognized in the New England Journal of Medicine,' said Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician and Professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital. 'Type 1 diabetes is a disease in which the immune system destroys the beta cells in pancreatic islets, requiring the patient to receive lifelong insulin therapy to control glucose levels. Although it is well established that pancreatic islet cell transplantation at a target therapeutic dose can predictably allow patients with type 1 diabetes to live without insulin therapy, until now these patients must take lifelong, significant immunosuppression, which is frequently toxic and difficult to tolerate. This study shows that Sana's novel HIP-modified pancreatic islets restore insulin production without the need for immunosuppression, a transformative outcome and significant step toward a broadly accessible, functional cure for patients with type 1 diabetes. The patient is making his own insulin for the first time in over 35 years.' 'These peer-reviewed results, built upon the extensive preclinical and translational studies of Dr. Sonja Schrepfer and the team at Sana, reinforce our belief that Sana has the capability to develop a functional cure for the broad population of individuals living with type 1 diabetes,' said Steve Harr, MD, Sana's President and Chief Executive Officer. 'The data, together with recent FDA feedback regarding our HIP-edited master cell bank for GMP manufacturing and our non-clinical testing plan for SC451, increase our confidence in our goal for treating type 1 diabetes—a single treatment with no immunosuppression that leads to long-term normal blood glucose without exogeneous insulin. We expect to file an IND for SC451, a next generation HIP-modified, stem cell-derived pancreatic islet therapy, as early as 2026 and begin Phase 1 testing shortly thereafter. I want to thank the entire Sana team, the investigators at Uppsala, and the patient who volunteered for this transformative, first-in-human study.' James Shapiro, M.D., Professor of Surgery, Medicine, and Surgical Oncology at the University of Alberta and leader of the clinical team that developed the Edmonton Protocol for islet cell transplantation, added 'Exogenous insulin therapy remains a lifesaving therapy in the short term, but it falls short of replicating the precise and dynamic glucose regulation of a healthy pancreas, leaving patients susceptible to both short- and long-term medical complications. This limitation motivated my team and me to pioneer a protocol for islet cell transplantation with immunosuppression and to continue innovating in this field. The data presented in the NEJM article—demonstrating that transplanted, engineered islet cells can both evade immune-mediated destruction and respond appropriately to insulin demands—represent a significant advancement in the ongoing pursuit of a definitive cure for type 1 diabetes and support my long-held belief that the future of type 1 diabetes treatment is in stem cell-based therapies.' Key Findings from Ongoing Study No serious adverse events or adverse events possibly or probably related to UP421 were identified in the study. HIP-modified pancreatic islet cells, transplanted with no immunosuppressive medicines, including no glucocorticoids, evade immune detection and rejection. Pancreatic islet cells survive and function post-transplantation. The survival and function of the HIP-modified pancreatic beta cells was confirmed at each blood draw, as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. C-peptide levels increase during monthly mixed meal tolerance tests (MMTT), showing increased insulin secretion in response to a meal. Of note, prior to transplant, the patient had undetectable C-peptide both when fasting and during an MMTT. MRI scans at each month show a sustained and consistent signal at the site of cell transplantation, consistent with graft survival. A PET-MRI scan with a tracer targeting pancreatic beta cells confirms that the surviving cells are, in fact, pancreatic beta cells. Sign in to access your portfolio
Yahoo
30-07-2025
- Yahoo
A type of HPV can cause skin cancer in people with weakened immune systems, report finds
Doctors at the National Institutes of Health have discovered a new cause of skin cancer, according to a case report published Wednesday in the New England Journal of Medicine. The culprit is a type of human papillomavirus (HPV) that's regularly found on the skin. It's long been thought to play a role in the development of skin cancer, but wasn't believed to be a direct cause. Skin cancer is caused by DNA damage in skin cells. The most common source of that damage is ultraviolet radiation from the sun. HPV can help UV-damaged DNA build up in cells and turn cancerous. However, in the new case report, doctors found that the virus itself could cause cancerous lesions to form. The discovery was made in a 34-year-old woman with a weakened immune system; experts said it's highly unlikely that HPV could play the same role in causing skin cancer in a person with a healthy immune system. 'The virus replicated in a somewhat uncontrolled manner and ended up integrating into the skin cells and once they did that, they became cancerous,' said Dr. Andrea Lisco, section chief of the mucosal and cutaneous viral immunopathogenesis unit at the National Institute of Allergy and Infectious Diseases, part of the NIH. Lisco was the woman's doctor and also the senior author of the case report. The woman had 43 spots of cutaneous squamous cell carcinoma — the second-most common type of skin cancer, after melanoma — on her face, hands and legs. She had surgery to remove the cancers and immunotherapy, but the cancer returned. When Lisco and his team biopsied several of her new tumors, they found that the woman's skin cancer was being driven by something they hadn't seen before: a group of HPVs called beta HPV. About 90% of people carry a strain of beta HPV. Usually, the virus lives on the skin and doesn't integrate into the DNA of skin cells. 'We shake hands and we pick up those viruses, but if our immune systems are under control, we are fine,' Lisco said. It's a different group of HPV strains — alpha HPVs — that are linked to a range of cancers. Alpha HPVs live on mucus membranes and can integrate into DNA, causing cancers of the cervix, anus, head and neck. The woman in the case report had a genetic condition that weakened her T-cells (a type of immune cell), leaving her immunocompromised. This allowed the beta HPV living on her skin to behave more like alpha HPV, integrating its DNA into her skin cells and replicating undisturbed, turning the cells cancerous. 'You don't know how much you can directly apply the information from one patient to the wide variety of patients,' said Dr. Anthony Oro, professor of dermatology at Stanford Medicine, who wasn't involved in the case. However, 'it suggests that, in the event that the T-cell arm of the immune system is not doing its job, beta-type HPV viruses could contribute to skin cancer, and maybe other kinds of cancers as well,' he said. The patient needed a stem cell transplant, which replaced her defective T-cells with T-cells that could prevent the HPV from replicating. 'We needed to give this patient a whole new immune system,' Lisco said. It worked. Three years post-transplant, the woman's skin cancer has not returned. 'It gives us good information about how the interplay of the HPV and the immune system works,' said Dr. Anthony Rossi, a dermatologist and Mohs surgeon at Memorial Sloan Kettering Cancer Center, who also wasn't involved with the woman's case. Doctors have known for a long time that some beta HPVs cause changes on the skin, such as warts on the hands and feet. 'HPV can integrate and cause changes in the cell cycle, especially in people with suppressed immune systems,' Rossi said. 'What was novel about this is that they found out it was a beta HPV that integrated into the DNA.' Other researchers have speculated this was a possibility based on studies in mice, but the new report shows that it can occur in humans. How many people could be at risk is still unknown. 'This is just one patient, and they have this unique situation of an immunological condition that enables the beta HPV to replicate unchecked,' Oro said. Other biopsies of squamous skin cancers have not detected HPV, meaning not all cases are caused by the viruses. Lisco said that the original notion — that HPV passively contributes to cutaneous squamous cell carcinoma by helping UV radiation damage skin cells, but doesn't actively help cancer grow — is still the likely explanation for many people. For them, 'protection from UV would be the prevention,' Lisco said — wearing sunscreen and covering up your skin from the sun — adding that immunocompromised people should be monitored more closely. People with weakened immune systems are as much as 100 times more likely to develop squamous cell carcinoma. The Gardasil HPV vaccine protects against nine strains of alpha HPV and has been shown to lower rates of cervical and head and neck cancers. It's unclear how much cross-protection, if any, the vaccine provides against other strains of HPV, including beta HPV. 'Even if this strain is not in the vaccine, there is some theory that there is cross-talk between HPV strains,' Rossi said. Most people will get HPV in their lifetimes. Scientists have so far identified about 200 unique strains of the virus. Alpha-HPV, with its well-established links to cancer, has thus far been the primary subject of research. 'This suggests that this other side of the family might also be important in situations where our immune system is not doing its job,' Oro said. This article was originally published on Solve the daily Crossword
30-07-2025
Ousted vaccine panel members say rigorous science is being abandoned
NEW YORK -- The 17 experts who were ousted from a government vaccine committee last month say they have little faith in what the panel has become, and have outlined possible alternative ways to make U.S. vaccine policy. U.S. Health Secretary Robert F. Kennedy Jr. abruptly fired the entire Advisory Committee on Immunization Practices, accusing them of being too closely aligned with manufacturers and of rubber-stamping vaccines. He handpicked replacements that include several vaccine skeptics. In a commentary published Wednesday in the New England Journal of Medicine, the former panel members wrote that Kennedy — a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official — and his new panel are abandoning rigorous scientific review and open deliberation. That was clear, they said, during the new panel's first meeting, in June. It featured a presentation by an anti-vaccine advocate that warned of dangers about a preservative used in a few flu vaccines, but the committee members didn't hear from Centers for Disease Control and Prevention staffers about an analysis that concluded there was no link between the preservative and neurodevelopmental disorders. The new panel recommended that the preservative, thimerosal, be removed even as some members acknowledged there was no proof it was causing harm. 'That meeting was a travesty, honestly,' said former ACIP member Dr. Yvonne Maldonado, a pediatric infectious diseases expert at Stanford University. The 17 discharged experts last month published a shorter essay in the Journal of the American Medical Association that decried Kennedy's 'destabilizing decisions." The focus was largely on their termination and on Kennedy's decision in May to stop recommending COVID-19 vaccines for healthy children and pregnant women. In the new commentary, the ousted committee members took it one step further and prescribed some steps that could be taken to maintain scientifically sound vaccine recommendations. 'An alternative to the Committee should be established quickly and — if necessary — independently from the federal government," they wrote. 'No viable pathway exists to fully replace the prior trusted and unbiased ACIP structure and process. Instead, the alternatives must focus on limiting the damage to vaccination policy in the United States.' Options included having professional organizations working together to harmonize vaccine recommendations or establishing an external auditor of ACIP recommendations. There are huge challenges to the ideas, including having access to the best data, the authors acknowledged. There's also the question of whether health insurers would pay for vaccinations that are recommended by alternative groups but not ACIP. They might pick and choose which vaccines to cover, said the University of North Carolina's Noel Brewer, another former ACIP member. For example, they might pay for vaccines that offer more immediate cost savings for health care, like the flu vaccine. 'But maybe not ones that have a longer-term benefit like HPV vaccine,' which is designed to prevent futures cancers, Brewer said. Officials with the U.S. Department of Health and Human Services did not immediately respond to a request for comment. ___
